These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 28687355)

  • 1. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
    Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
    Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid Biopsies for Assessing Metastatic Melanoma Progression.
    Huynh K; Hoon DS
    Crit Rev Oncog; 2016; 21(1-2):141-54. PubMed ID: 27481010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients.
    Marsavela G; Reid A; Gray ES; Calapre L
    Methods Mol Biol; 2021; 2265():247-263. PubMed ID: 33704720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid Biopsy for the Management of Patients with Colorectal Cancer.
    Yamada T; Matsuda A; Koizumi M; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Yokoyama Y; Hara K; Hotta M; Matsumoto S; Yoshida H
    Digestion; 2019; 99(1):39-45. PubMed ID: 30554222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma.
    De Simoni E; Spagnolo F; Gandini S; Gaeta A; Rizzetto G; Molinelli E; Simonetti O; Offidani A; Queirolo P
    Cancer Treat Rev; 2024 Sep; 129():102788. PubMed ID: 38908229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
    Gingras I; Salgado R; Ignatiadis M
    Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
    Huang SK; Hoon DS
    Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Circulating Tumor DNA Analysis.
    Perakis S; Auer M; Belic J; Heitzer E
    Adv Clin Chem; 2017; 80():73-153. PubMed ID: 28431643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.
    Xu MJ; Dorsey JF; Amaravadi R; Karakousis G; Simone CB; Xu X; Xu W; Carpenter EL; Schuchter L; Kao GD
    Oncologist; 2016 Jan; 21(1):84-94. PubMed ID: 26614709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.
    Busser B; Lupo J; Sancey L; Mouret S; Faure P; Plumas J; Chaperot L; Leccia MT; Coll JL; Hurbin A; Hainaut P; Charles J
    Biomed Res Int; 2017; 2017():5986129. PubMed ID: 28484715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
    Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
    Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
    Takai E; Yachida S
    World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research progress on liquid biopsy in oncology and its clinical applications.
    Wang C; Li YM; Fang XD
    Yi Chuan; 2017 Mar; 39(3):220-231. PubMed ID: 28420618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.